The Technical Analyst
Odonate Therapeutics Inc [ODT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Odonate Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.27% $1.120
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-03-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.413 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.413 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.965 - 1.275 ( +/- 13.84%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-12-01 | Ecor1 Capital, Llc | Buy | 185 941 | Common Stock |
| 2021-12-01 | Ecor1 Capital, Llc | Sell | 185 941 | Common Stock |
| 2021-12-09 | Ecor1 Capital, Llc | Sell | 156 669 | Common Stock |
| 2021-12-10 | Ecor1 Capital, Llc | Sell | 5 000 000 | Common Stock |
| 2021-12-10 | Ecor1 Capital, Llc | Sell | 545 000 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 99 transactions |
| Buy: 1 597 913 | Sell: 11 234 741 |
Forecast:
01:40 - $1.230
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.120 (-4.27% ) |
| Volume | 0.716 mill |
| Avg. Vol. | 0.960 mill |
| % of Avg. Vol | 74.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ODT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ODT
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2021-08-13 09:00:00 - Press Release
Shareholder Alert: Odonate Therapeutics, Inc. (odt) Officers And Directors Under Investigation For Possible False Statements To Investors
San francisco, aug. 13, 2021 /prnewswire/ -- schubert jonckheer & kolbe llp is investigating potential derivative claims on behalf of shareholders of odonate therapeutics, inc. (nasdaq: odt) relating to possible false statements to investors regarding its only product, tesetaxel, a drug the company was formerly developing for the treatment of breast cancer. a securities class action in the u.s. district court for the southern district of california recently survived a motion to dismiss allegations that between december 7, 2017 and march 19, 2021, odonate and its ceo, cfo, and coo made false and misleading statements about the safety of tesetaxel, which was then undergoing a phase 3 clinical trial for the treatment of breast cancer.
2021-08-06 19:17:00 - Press Release
The Law Offices Of Frank R. Cruz Announces Investigation Of Odonate Therapeutics, Inc. (odt) On Behalf Of Investors
Los angeles--(business wire)---- $odt #investors--the law offices of frank r. cruz announces investigation of odonate therapeutics, inc. (odt) on behalf of investors
2021-02-23 08:30:00 - Press Release
Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2020
New york--(business wire)--odonate therapeutics, inc. (nasdaq: odt), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended december 31, 2020. as of december 31, 2020, odonate had $157.3 million in cash, compared to $180.5 million as of december 31, 2019. this decrease in cash resulted primarily from cash used in operating activities for
2020-12-11 10:05:00 - Press Release
Positive Results Of Contessa, A Phase 3 Study Of Tesetaxel In Patients With Metastatic Breast Cancer, Presented At The 2020 San Antonio Breast Cancer Symposium (sabcs)
San diego--(business wire)--odonate therapeutics, inc. (nasdaq: odt), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer, today announced that positive results from contessa, a phase 3 study of tesetaxel in patients with metastatic breast cancer (mbc), were presented in an oral presentation at the 2020 san antonio breast cancer symposium (sabcs). the results were presented by joyce o'shaughnessy, m.d., ce
2020-12-07 08:30:00 - Press Release
Odonate Therapeutics Initiates Cohort 3 Of Contessa Trio To Evaluate Tesetaxel Monotherapy In Patients With Metastatic Breast Cancer
San diego--(business wire)--odonate therapeutics, inc. (nasdaq: odt), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of cohort 3 of contessa trio, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (her2)-negative metastatic breast cancer (mbc). cohort 3 of contessa trio will complement cohort
Latest News
2022-01-07 13:49:39 - Pulse2
Odonate Therapeutics Stock (ODT): Why The Price Plummeted Today
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) fell by over 17% during intraday trading today. This is why it happened.
2021-08-13 09:00:00 - PRNewsWire
SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors
SAN FRANCISCO, Aug. 13, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) relating to possible false statements to investors regarding its only product, tesetaxel, a drug the company was formerly developing for the treatment of breast cancer. A securities class action in the U.S. District Court for the Southern District of California recently survived a motion to dismiss allegations that between December 7, 2017 and March 19, 2021, Odonate and its CEO, CFO, and COO made false and misleading statements about the safety of tesetaxel, which was then undergoing a Phase 3 clinical trial for the treatment of breast cancer.
2021-08-06 19:17:00 - Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ODT #investors--The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
2021-07-06 10:16:08 - Benzinga
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.
2021-07-06 07:42:20 - Pulse2
ODT Stock Price Increases Over 20% Pre-Market: Details
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) increased by over 20% pre-market. These are some details you should know.
2021-07-05 12:29:05 - PennyStocks
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
2021-05-11 12:59:59 - GuruFocus
3 Net Current Asset Value Stock Picks
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised the share prices to near or above the liquidation value.
2021-05-06 09:01:57 - Zacks Investment Research
Odonate Therapeutics (ODT) Enters Oversold Territory
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
2021-04-27 05:43:16 - Seeking Alpha
Odonate Therapeutics: Lessons Learned
2021-04-09 08:19:21 - Zacks Investment Research
Odonate Therapeutics (ODT) is Oversold: Can It Recover?
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.